Oncolytics Biotech Inc T.ONC

Investor Presentation just updated

[caddisdm]

ONC Investor presentation updated to November.

[Noteable]

By 2030, sales in HR+ / HER2- breast cancer are projected to grow 280% to US$31 Billion vs.US$11 Billion in 2020. Source:: 2022 Breast Cancer Disease Landscape & Forecast, (Clarivate, 2022) https://d1io3yog0oux5.cloudfront.net/_06b5bc90d8866abe952bdbdef7d0e190/oncolyticsbiotech/db/300/2536/pdf/Oncolytics+Corporate+Presentation+Nov_17.pdf

[Quentin30]

What % cost of a combination treatment do you calculate Pela to be Noteable.? It is that figure, that ultimately will value ONCY, not fantasy buyout numbers. I just wondered if you'd even considered this and have ever shared such an opinion on this BB. Let's face it, getting a product approved is great, but if it only brings in peanuts then what is the company worth. THIS is going to

[Kswdelux]

I can only speculate, but because ONC is not part of any combination therapy that are approved at that time in those numbers that were run, and ONC is really a weird new up and coming science.... that the addition of pela to the mix might be an added costs above that number. and if pela makes 75% of those drugs all work better Well.... $$$

[askretka]

If you look at older Douglas Loe reports he's expecting Earnings for ONC of over 6$ per share on Royalties from Breast Cancer, Pancreatic Cancer and Myeloma in 2030. ------ At 20x earnings that's a 120$ a share stock in 2030. ---------- That includes nothing for CAR-T and nothing for China Breast Cancer deal so far. ----------- I don't think Big Pharma will want to pay those Royalties

[westcoast1000]

Quentin, It is not simply the price per unit of treatment for pela. It is also expansion of the number of suitable patients, as well as the improved efficacy.